Dr. Patricia Jones, right, and Hayley McLean, master of science in public health student and Dr. Jones’ graduate research assistant.

Liver Cancer Disparities: A Complicated Picture


Hepatocellular carcinoma, the most common type of liver cancer, is a critical health problem in the United States and the fifth leading cause of cancer deaths. However, the disease does not affect all groups equally and nobody is really sure why.

Sylvester Survivorship Celebration on August 3, 2019 at Marlins Park.

Helping Cancer Survivors in Transition


Cancer survivors in the U.S. currently number 17 million, with that number expected to climb to 26 million within the next 20 years. As defined by the National Cancer Institute, cancer survivorship care focuses on the health and life of a person following initial treatment through the end of life. It covers the physical, psychosocial, and economic issues of cancer, beyond the diagnosis and initial treatment phases.

Dr. Tan Ince

HDAC7 Gene Plays a Critical Role in Breast Cancer Stem Cells


In a study recently published in the journal Oncogene, a research team led by Tan Ince, M.D., Ph.D., described the mechanisms that help the gene histone deacetylase (HDAC) 7 control other genes, driving breast cancer and helping maintain cancer stem cells. In addition, the paper showed HDAC7 activity is downstream from other HDAC molecules, particularly HDAC1, possibly making it a better therapeutic target for future

Standing, from left: President Julio Frenk, Edward Abraham, M.D., Annette de la Renta, and Henri R. Ford, M.D. Seated: Stephen D. Nimer, M.D.

Dr. Stephen D. Nimer Honored with Endowed Chair


Dr. Stephen D. Nimer, director of Sylvester Comprehensive Cancer Center, which recently received a prestigious designation from the National Cancer Institute, has been named the inaugural holder of the Oscar de la Renta Endowed Chair in Cancer Research.

Dr. Stephen D. Nimer in the lab.

Sylvester Research Identifies Novel Vulnerability in Acute Leukemia Cells


Researchers at the NCI-designated Sylvester Comprehensive Cancer Center, working within several departments at the University of Miami Miller School of Medicine, have identified another critical component of the AML1-ETO multi-protein complex that could point the way to more effective therapies for acute myeloid leukemia (AML).

Sylvester Researchers Find PARP Inhibitors Could Be a New Treatment for a Common Lymphoma


A study looking at PARP inhibition in diffuse large B cell lymphoma opens the door to a new way to treat this common type of cancer, according to study author Izidore S. Lossos, M.D., endowed director of the Lymphoma Program at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and head of the Hematological Malignancies Site Disease Group.